Pharmaceuticals

New 48-week data for envudeucitinib shows 54% of patients achieved complete skin clearance, setting a new bar for oral therapies and positioning Alumis for market disruption.

Strong Attruby sales and new data showing superiority fuel BridgeBio’s momentum as it prepares for three FDA decisions, backed by a new $1B financing.

Two years after a landmark rejection, the bid to approve MDMA-assisted therapy for PTSD is back. This is more than a resubmission; it's a test case for a new paradigm in medicine.

AOM Capital's recent $5.1M financing for a drug acquisition showcases the rise of specialty lenders in the high-stakes world of pharmaceutical M&A.

Indian pharma giant Lupin secures FDA approval for a generic heart drug, challenging AstraZeneca and signaling a new era of cost competition in specialty medicine.

ITM’s promising cancer drug ITM-11 hits a delay, not for its science, but for manufacturing. A classic 'prototype to profit' hurdle with big implications.

Bristol Myers Squibb's massive Texas campus isn't just about jobs. It's a high-tech play to reshore drug manufacturing and revolutionize how we make medicine.

Heron Therapeutics withdraws guidance after a patent blow to its top drug, forcing a strategic review. Can strong growth in new acute care products save it?

Amid its pending sale to Zymeworks, Theravance Biopharma’s Q2 results reveal a lesson in resilience, with strong YUPELRI sales and deep cost cuts.

A new drug, divesiran, shows stunning success in trials, offering hope to those with a rare blood cancer by potentially replacing frequent phlebotomies with a quarterly shot.

Health Canada's approval of Fasenra for HES marks a new era for patients. This is the story of how one drug intersects with patient hope and national policy.

Grifols completes its landmark SPARTA trial for a rare lung disease, offering new hope to patients and signaling a major strategic move in the biotech market.

A Korean firm's breakthrough tech bypasses freezing temps for vaccines. This isn't just a business win; it's a blueprint for a more accessible future.

With a key leadership hire, UK's Reacta Healthcare leverages its pharma-grade advantage to scale R&D and transform the global food allergy testing landscape.

Partner Ocumension submits NCX 470 for approval, a move poised to tap into a massive patient market and validate Nicox's global commercialization strategy.

A key partner's FDA stumble could have derailed a vital new SMA drug. Instead, Scholar Rock's foresight kept the approval on track, showing why it pays to plan for the worst.

Braveheart Bio's stunning IPO debut raised nearly half a billion dollars. We dig into the story behind the numbers and what it signals for the 2026 economy.

NRx Pharmaceuticals announces a key FDA milestone for its ketamine therapy. This is a critical step, but the path to patient access is complex.

A landmark clinical trial for Progressive Supranuclear Palsy has begun. We deconstruct the novel platform design that offers new hope against a devastating disease.

For a rare brain disease with no cure, a revolutionary trial design offers a faster path to treatment and renewed hope for thousands of patients and families.